Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.52 |
| ▸ | RORC | P51449 | 3/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL600298 | 0.82 | CNR2 (0.77) | CNR2PTGS2MAPTTP53MEN1 | |
| SCHEMBL600940 | 0.81 | PLA2G2A (0.57) | CNR2RORCMAPTPLA2G2ANPC1 | |
| SCHEMBL602524 | 0.80 | CNR2 (0.56) | CNR2RORCPLA2G2ANPC1CNR1 | |
| SCHEMBL600236 | 0.77 | CNR2 (0.69) | CNR2PLA2G2ACNR1 | |
| SCHEMBL602385 | 0.73 | PLA2G2A (0.54) | CNR2RAB9APLA2G2ANPC1CNR1 | |
| SCHEMBL16562294 | 0.72 | KMT2A (0.70) | MAPTRAB9APOLBNPC1MEN1 | |
| SCHEMBL7629275 | 0.70 | RORC (0.53) | CNR2RORCMAPTTP53NPC1 | |
| SCHEMBL3868213 | 0.69 | MCHR1 (0.70) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL600414 | 0.69 | CNR2 (1.00) | CNR2RORCMAPTTP53CNR1 | |
| SCHEMBL29189093 | 0.68 | PTGS2 (1.00) | PTGS2MAPTPLA2G2ATP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170096426-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | THE UNIV OF MONTANA (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170096426-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | THE UNIV OF MONTANA (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170096426-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | THE UNIV OF MONTANA (US) | 2017-04-06 | — | — | US | disclosed |
| US-20120039804-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-02-16 | — | — | US | disclosed |
| US-20120039804-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-02-16 | — | — | US | disclosed |
| US-20120039804-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120039804-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | CNR1, CNR2, OPRL1 | CNR2 2/4885RORC 824/4885PTGS2 947/4885 |
| US-20170096426-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | CNR1, CNR2, OPRL1 | CNR2 2/4885RORC 824/4885PTGS2 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.